Cited by 1,625COVID-19 Clinical Research StudiesRespiratory Support and MechanismsSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Open access

Geleris, Joshua, Sun, Yifei, Platt, Jonathan, Zucker, Jason, Baldwin, Matthew, Hripcsak, George, Labella, Angelena, Manson, Daniel K., Kubin, Christine, Barr, R. Graham, Sobieszczyk, Magdalena E., Schluger, Neil W.·2020·New England Journal of Medicine

DOI 10.1056/nejmoa2012410PMC PMC7224609

Open this paper in CoChat — free account

Abstract

BACKGROUND: Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. METHODS: We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS: Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours. Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses. CONCLUSIONS: In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed. (Funded by the National Institutes of Health.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2012410

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Gautret, P., Lagier, J., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Esteves-Vieira, V., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
Retracted
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L. Y., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,696
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
Devaux, C. A., Rolain, J., Colson, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105938 · Cited by 1,122
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trialPreprint
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 861
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed Central · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 662
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
Fantini, J., Scala, C. D., Chahinian, H., & Yahi, N. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105960 · Cited by 566
Mechanism of action of hydroxychloroquine as an antirheumatic drug
Fox, R. I. (1993) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(10)80012-5 · Cited by 430
Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities
Biot, C., Daher, W., Leleu‐Chavain, N., Fandeur, T., Khalife, J., Dive, D., & Clercq, E. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0601856 · Cited by 318

Flagged first, then by citations

Show all 17 references

Sorted by citations

Items 901–1,000 of 1,000

The association between creatinine to body weight ratio and the risk of progression to diabetes from pre-diabetes: a 5-year cohort study in Chinese adults
Li, T., Cao, C., Xuan, X., Liu, W., Xiao, X., & Wei, C. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01518-9 · Cited by 9
Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19
Hanna, G. J., Rettig, E. M., Park, J. C., Varvares, M. A., Lorch, J. H., Margalit, D. N., Schoenfeld, J. D., Tishler, R. B., Goguen, L. A., Annino, D. J., et al. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105087 · Cited by 9
Basic Critical Care for Management of COVID-19 Patients: Position Paper of the Indian Society of Critical Care Medicine, Part II
Ramasubban, S., Juneja, D., Dixit, S., Reddy, P. K., Gopal, P. B. N., Savio, R. D., & Singh, M. K. (2020) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23593 · Cited by 9
Perfil demográfico e clínico de pacientes com diagnóstico de COVID-19 em um hospital público de referência na cidade de Fortaleza-Ceará
Rebouças, E. R. N., da Costa, R. F., Miranda, L. R., & Campos, N. G. (2020) · Journal of Health & Biological Sciences · doi:10.12662/2317-3076jhbs.v8i1.3438.p1-5.2020 · Cited by 9
Decreased serum ACE2 levels in patients with connective tissue diseases
Tang, X., Geng, L., Feng, X., & Sun, L. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa898 · Cited by 9
A alimentação coletiva como espaço de saúde pública: os riscos sanitários e os desafios trazidos pela pandemia de Covid-19
Abranches, M. V., Oliveira, T. C., & José, J. F. B. D. S. (2021) · Interface - Comunicação Saúde Educação · doi:10.1590/interface.200654 · Cited by 9
Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections
Kolli, A. R., Calvino-Martin, F., & Hoeng, J. (2022) · Pharmaceutical Research · doi:10.1007/s11095-021-03152-3 · Cited by 9
Current therapies under investigation for COVID-19: potential COVID-19 treatments
Weisberg, E., Sattler, M., Yang, P. L., Parent, A., Gray, N. S., & Griffin, J. D. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0286 · Cited by 9
Beyond the operating room: the roles of anaesthesiologists in pandemics
Ortega, R., & Chen, R. B. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.06.005 · Cited by 9
Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al
Notz, Q., Meybohm, P., Kranke, P., Weismann, D., Lotz, C., & Schmalzing, M. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218778 · Cited by 9
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trialPreprint
Grau-Pujol, B., Camprubí-Ferrer, D., Martí-Soler, H., Fernández-Pardos, M., Carreras‐Abad, C., Andrés, M. V., Ferrer, E., Muelas‐Fernandez, M., Jullien, S., Barilaro, G., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-72132/v1 · Cited by 9
COVID-19 reveals Brugada pattern in an adolescent patient
Choi, N. H., Silver, E. S., Fremed, M. A., & Liberman, L. (2020) · Cardiology in the Young · doi:10.1017/s1047951120002619 · Cited by 8
Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19
Afşin, A., Ecemiş, K., & Asoğlu, R. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4288 · Cited by 8
Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients
Tchana‐Sato, V., Ancion, A., Tridetti, J., Sakalihasan, N., Hayette, M., Detry, O., Delvenne, P., Amabili, P., Sénard, M., Hougrand, O., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05793-6 · Cited by 8
The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 –a systematic review and meta-analysis
Choudhuri, A. H., Duggal, S., Ahuja, B., & Biswas, P. S. (2021) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2021.03.002 · Cited by 8
Propensity score analysis of red cell distribution width to serum calcium ratio in acute myocardial infarction as a predictor of in-hospital mortality
Huang, S., Zhang, H., Zhuang, Z., Guo, N., Zhou, Q., Duan, X., & Ge, L. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1292153 · Cited by 8
Resilience and response of the congenital cardiac network in Italy during the COVID-19 pandemic
Formigari, R., Marcora, S. A., Luciani, G. B., Favilli, S., Assenza, G. E., Rinelli, G., Meliota, G., Castaldi, B., Limongelli, G., Flocco, S. F., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001063 · Cited by 8
Severe arterial thromboembolism in patients with Covid-19
Lameijer, J. R. C., van Houte, J., van Berckel, M. M. G., Canta, L. R., Yo, L. S. F., Nijziel, M. R., Krietemeijer, G. M., Troquay, S., Buise, M. P., & Hendriks, J. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.08.002 · Cited by 8
Clinical Experience with COVID-19 at a Specialty Orthopedic Hospital Converted to a Pandemic Overflow Field Hospital
Miller, A. O., Kapadia, M., Kirksey, M., Sandhu, M. S., Jannat‐Khah, D., Bui, T., Boyle, K. K., Krez, A. N., Russell, L., O'Neill, J., et al. (2020) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-020-09779-z · Cited by 8
No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19
Faíco-Filho, K. S., Conte, D., Luna, L. K. D. S., Carvalho, J. M. A., Perosa, A. H., & Bellei, N. (2020) · Brazilian Journal of Microbiology · doi:10.1007/s42770-020-00395-x · Cited by 8
Managing hyperglycemia during the COVID-19 pandemic: Improving outcomes using new technologies in intensive care
Valk, T. W., & McMorrow, C. (2020) · SAGE Open Medicine · doi:10.1177/2050312120974174 · Cited by 8
Coronavirus 2019: clinical and neuropathological aspects
Younger, D. S. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000769 · Cited by 8
Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan
Maneikis, K., Ringelevičiūtė, U., Bacevičius, J., Dieninyte-Misiune, E., Burokaitė, E., Kazbaraitė, G., Janusaite, M. M., Dapkevičiūtė, A., Žučenka, A., Pečeliūnas, V., et al. (2020) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2020.100685 · Cited by 8
Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics
Natanegara, F., Zariffa, N. M.-D., Buenconsejo, J., Liao, R., Cooner, F., Lakshminarayanan, D., Ghosh, S., Schindler, J. S., & Gamalo, M. (2020) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2020.1865195 · Cited by 8
Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection
Awad, N., Schiller, D. S., Fulman, M., & Chak, A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab056 · Cited by 8
Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City
Lozano-Cruz, O. A., Jiménez, J. V., Olivas‐Martínez, A., Ortíz‐Brizuela, E., Cárdenas-Fragoso, J. L., Azamar‐Llamas, D., Rodríguez‐Rodríguez, S., Oseguera-Moguel, J., Dorantes-García, J., Barrón-Magdaleno, C., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.668678 · Cited by 8
Factors associated with psychiatric admission and subsequent self-harm repetition: a cohort study of high-risk hospital-presenting self-harm
Cully, G., Corcoran, P. E., Leahy, D., Cassidy, E., Steeg, S., Griffin, E., Shiely, F., & Arensman, E. (2021) · Journal of Mental Health · doi:10.1080/09638237.2021.1979488 · Cited by 8
New In Silico Insights into the Application of (Hydroxy)Chloroquine with Macrolide Antibiotic Co-Crystals against the SARS-CoV-2 Virus
de Castro, A. A., de Assis, L. C., da Cunha, E. F. F., Ramalho, T. C., & Porta, F. A. L. (2022) · COVID · doi:10.3390/covid2030018 · Cited by 8
Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation
La, J., Fillmore, N. R., Do, N., Brophy, M. T., Monach, P. A., & Branch‐Elliman, W. (2022) · Health Research Policy and Systems · doi:10.1186/s12961-022-00935-x · Cited by 8
An In silico Investigation to Identify Promising Inhibitors for SARS-CoV-2 Mpro Target
Alagarsamy, V., Sundar, P. S., Narendhar, B., Sulthana, M. T., Kulkarni, V. S., Aishwarya, A. D., Solomon, V. R., Murugesan, S., Selvaraj, J., Rohitha, K., et al. (2023) · Medicinal Chemistry · doi:10.2174/1573406419666230413112802 · Cited by 8
Tratamiento farmacológico para COVID-19 en protocolos latinoamericanos: Una revisión narrativa de la eficacia y seguridad
Centro Brasileiro de Informação sobre Medicamentos, C. F. D. F. B., Saavedra, P. A. E., Cañás, M., CIMEFF Área de Farmacología, F. M. D. L. P. D. B. A. (., Barbado, D. M. C., Asesora independiente, B., Esparza, L. B., Instituto de Ciencias de la Salud, U. A. D. E. D. H., Caffaratti, M., Centro de Información de Medicamentos, F. D. C. Q., et al. (2020) · doi:10.22239/2317-269x.01741 · Cited by 8
Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence
Hoang, T., & Tran, T. T. A. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.3.317 · Cited by 8
Content-Aware Galaxies: Digital Fingerprints of Discussions on Social Media
Babvey, P., Borrelli, D., Lipizzi, C., & Ramírez-Márquez, J. E. (2020) · IEEE Transactions on Computational Social Systems · doi:10.1109/tcss.2020.3024762 · Cited by 8
Actualización de la Declaración de consenso en medicina critica para la atención multidisciplinaria del paciente con sospecha o confirmación diagnóstica de COVID-19
Mendoza, J. L., Estrada, V. H. N., López, N. B., Bolaños, E. R., Franco, D. M., Castell, C. R. D., Moreno, A. A. V., Amaya, I., Flórez, J. S., VALENCIA, B. A. G., et al. (2020) · Acta Colombiana de Cuidado Intensivo · doi:10.1016/j.acci.2020.09.004 · Cited by 8
Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19
Myint, P. K., Carter, B., Barlow-Pay, F., Short, R., Einarsson, A., Bruce, E., McCarthy, K. L., Verduri, A., Collins, J., Hesford, J., et al. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620985690 · Cited by 8
Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2
Shu, C., 南京211166，中国, 南., Huang, X., Tang, H., Mo, D., Zhou, J., Deng, C., 210023，中国, 南. 南., 211166，中国, 南. 南., 211166，中国, 南. 南., et al. (2021) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.301 · Cited by 8
Predicting the 7th Day Efficacy of Acupoint Application of Chinese Herbs (Xiao Zhong Zhi Tong Tie) in Patients with Diarrhea – A Machine-Learning Model Based on XGBoost Algorithm
Xu, F.-Q., Song, S., Li, R., Wang, X., Gao, H., & Zhang, Y.-H. (2021) · World Journal of Traditional Chinese Medicine · doi:10.4103/wjtcm.wjtcm_60_21 · Cited by 8
Can Anti-Parasitic Drugs Help Control COVID-19?
Panahi, Y., Dadkhah, M., Talei, S., Gharari, Z., Asghariazar, V., Abdolmaleki, A., Matin, S., & Molaei, S. (2022) · Future Virology · doi:10.2217/fvl-2021-0160 · Cited by 8
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function
Miller‐Handley, H., Luckett, K. M., & Govil, A. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2020.09.001 · Cited by 8
COVID-19 Pandemic in Brazil: History, Characteristics, and Evolution
Serdan, T. D. A., Tang, Y., Lobato, T. B., da Silva, F. L. R., Tang, S., Masi, L. N., Gorjão, R., Palacios, R., Pithon‐Curi, T. C., Curi, R., et al. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-71697-4_3 · Cited by 8
Pediatric COVID-19
Al-Hajjar, S. H., & MCINTOSH, K. (2020) · International Journal of Pediatrics and Adolescent Medicine · doi:10.1016/j.ijpam.2020.05.001 · Cited by 8
Hydroxychloroquine in COVID-19: An updated systematic review with meta-analysisPreprint
Chacko, J., Brar, G., & Premkumar, R. (2020) · medRxiv · doi:10.1101/2020.05.14.20101774 · Cited by 8
Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma
Medina, M. T., & Moncada, S. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116972 · Cited by 8
Quinoline-Based FDA-Approved Drugs: Synthetic Route and Clinical Uses
Chandra, D., Sachin, S., Rav, S., & Sharma, U. K. (2025) · Synlett · doi:10.1055/a-2564-4559 · Cited by 7
Ongoing initiatives to improve the prescribing of medicines across sectors and the implications
Godman, B. (2020) · Advances in Human Biology · doi:10.4103/aihb.aihb_90_20 · Cited by 7
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
Kröker, A., & Tirzīte, M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01885-8 · Cited by 8
Hydroxychloroquine and Remdesivir in COVID-19: A critical analysis of recent events
Dang, A., Vallish, B., & Dang, S. (2020) · Indian Journal of Medical Ethics · doi:10.20529/ijme.2020.068 · Cited by 7
Prospects for a COVID-19 treatment: review
Starshinova, A. A., Kushnareva, E. A., Kudlay, D. A., & Dovgalyuk, I. F. (2020) · Translational Medicine · doi:10.18705/2311-4495-2020-7-3-30-37 · Cited by 7
Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms
Berkman, S. A., & Tapson, V. F. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620945398 · Cited by 7
Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis combining 66 trials
Wu, S., Zhou, Q., Zeng, X., Zhang, J.-X., Yang, Z., Yang, Q., Zhang, Z.-L., Chen, Y., Sun, F., & Zhan, S.-Y. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001672 · Cited by 7
The Trilogy of SARS-CoV-2 in Pediatrics (Part 1): Acute COVID-19 in Special Populations
Parsons, S., & Tran, V. L. (2021) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-26.3.220 · Cited by 7
How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols
Asundi, A., Resnik, J., Benedict, P. A., Shin, M. H., Elwy, A. R., & Branch‐Elliman, W. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab072 · Cited by 7
The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data
Tang, W., Khalili, L., Giles, J. T., Gartshteyn, Y., Kapoor, T. M., Guo, C., Chen, T., Theodore, D., & Askanase, A. (2021) · Rheumatology and Therapy · doi:10.1007/s40744-021-00315-x · Cited by 7
The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study
Pan, C., Chen, H., Xie, J., Huang, Y., Yang, Y., Du, B., & Qiu, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.822821 · Cited by 7
Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness
Asaikkutti, A., Vimala, K., Dhineshkumar, E., Cheruparambath, P., Balakrishnan, K., & Arul, V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104567 · Cited by 7
Fluorometric and colorimetric platforms for rapid and sensitive hydroxychloroquine detection in aqueous samples
Doğan, K., Taş, D. Ü., Çetinkol, Ö. P., & Forough, M. (2023) · Talanta · doi:10.1016/j.talanta.2023.125523 · Cited by 7
Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective
Chakraborty, A., Ghosh, R., Mohapatra, S. S., Barik, S., Biswas, A., & Chowdhuri, S. (2024) · Gene · doi:10.1016/j.gene.2024.148553 · Cited by 7
Severe Acute Respiratory Syndrome Coronavirus-2 Cardiovascular Complications: Implications for Cardiothoracic Anesthesiology
Cormican, D. S., Winter, D., McHugh, S. M., Sonny, A., Crowley, J., Yu, R., Barrack, F., Nuñez-Gil, I. J., & Ramakrishna, H. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.05.035 · Cited by 7
Tratamento precoce para COVID-19 baseado em evidência científica
Vieira, S. C., Fontinele, D. R. D. S., Barjud, M. B., de Carvalho, J. M., Melo, L. M. C., Filho, J. W. F., Prado, G. L. M., & Alencar, A. A. (2020) · Revista Brasileira em Promoção da saúde · doi:10.5020/18061230.2020.10993 · Cited by 7
Comparison of COVID-19 Health Risks With Other Viral Occupational Hazards
Unger, J. (2020) · International Journal of Health Services · doi:10.1177/0020731420946590 · Cited by 7
Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective
Manchanda, K., Singh, J., Bhagat, R., Tiwana, I. K., & Singh, H. (2020) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200060 · Cited by 7
COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases
Raza, H. A., Tariq, J., Agarwal, V., & Gupta, L. (2021) · Rheumatology International · doi:10.1007/s00296-020-04759-2 · Cited by 7
COVID-19 Pandemic and Virtual Clinics for Diabetes Care
Garg, S. K., & Reinicke, T. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.2501 · Cited by 7
Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans
Gerlovin, H., Posner, D. C., Ho, Y.-L. A., Rentsch, C. T., Tate, J. P., King, J. T., Kurgansky, K. E., Danciu, I., Costa, L., Linares, F., et al. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab183 · Cited by 7
Antimalarial drugs—are they beneficial in rheumatic and viral diseases?—considerations in COVID-19 pandemic
Grygiel‐Górniak, B. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05805-5 · Cited by 7
Cardiovascular involvement in patients with 2019 novel coronavirus disease
Li, C., Wang, D. W., & Zhao, C. (2021) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2021-0016 · Cited by 7
Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso
Rouamba, T., Ouédraogo, E., Barry, H., Yaméogo, N. V., Sondo, A. K., Boly, R., Zoungrana, J., Ouédraogo, A. R., Tahita, M. C., Poda, A., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.02.034 · Cited by 7
High-cited favorable studies for COVID-19 treatments ineffective in large trials
Ioannidis, J. P. A. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2022.04.001 · Cited by 7
Basic Critical Care for Management of COVID-19 Patients: Position Paper of Indian Society of Critical Care Medicine, Part-I
Singh, M., Ramasubban, S., Juneja, D., Reddy, P. K., Gopal, P. B. N., Savio, R. D., & Dixit, S. (2020) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23601 · Cited by 7
Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses
Jeong, J. H., Choi, J., Kim, B. K., Min, S. C., Chokkakula, S., Oh, S., Park, J., Shim, S., Kim, E., Choi, Y. K., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105669 · Cited by 7
Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far
Dhampalwar, S., Saigal, S., & Soin, A. S. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.07.001 · Cited by 7
COVID-19 and clinical pharmacology
Колбин, А. С. (2020) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2020-3-14-24 · Cited by 7
Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States
Rhodes, N. J., Dairem, A., Moore, W. J., Shah, A., Postelnick, M. J., Badowski, M. E., Michienzi, S. M., Borkowski, J., Polisetty, R. S., Fong, K., et al. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa426 · Cited by 7
Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19
Shetty, R. M., & Namachivayam, A. (2021) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23773 · Cited by 7
In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel—A Drug Antitarget
Al‐Moubarak, E., Sharifi, M., & Hancox, J. C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.645172 · Cited by 7
Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study
Guillaume, D., Bouvet, M., Sina, E., Salah-Mabed, I., Frédéric, V., Mathieu, D., Muselier, A., Yoni, G., Emma, E., Charlotte, B., et al. (2021) · Rheumatology and Therapy · doi:10.1007/s40744-021-00373-1 · Cited by 7
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma ConcentrationsPreprint
Marzolini, C., Stader, F., Stoeckle, M. P., Franzeck, F. C., Egli, A., Bassetti, S., Hollinger, A., Osthoff, M. F., Weisser, M., Gebhard, C. E., et al. (2020) · medRxiv · doi:10.1101/2020.07.05.20146878 · Cited by 7
Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA PandemicPreprint
Smith, L. G., Mendoza, N., DOBESH, D. P., & Smith, S. M. (2021) · medRxiv · doi:10.1101/2021.05.28.21258012 · Cited by 7
Quantifying Potential Immortal Time Bias in Observational Studies in Acute Severe Infection
Yates, T., Parks, T., & Dodd, P. J. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf173 · Cited by 6
Association between systemic immune-inflammation index and disease activity score 28 in patients with rheumatoid arthritis: a cross-sectional study
Li, X., Leng, L., Han, Y., Zhang, J., Shen, J., An, L., Li, L., & Qiao, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-30053-x · Cited by 6
RETRACTED: Antiviral treatment could not provide clinical benefit in management of mild COVID-19: A Retrospective Experience from Field hospital
Aumpan, N., Vilaichone, R., Ratana‐Amornpin, S., Teerakapibal, S., Toochinda, P., Witoonchart, G., & Nitikraipot, S. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.07.019 · Cited by 6
Retracted
MSC–extracellular vesicle microRNAs target host cell-entry receptors in COVID-19: in silico modeling for in vivo validation
AlSaihati, H., Dessouky, A. A., Salim, R. F., Elgohary, I., El-Sherbiny, M., Ali, F. E. M., Moustafa, M. M. A., Shaheen, D., Forsyth, N. R., Badr, O. A. M., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03889-9 · Cited by 6
A detailed examination of coronavirus disease 2019 (COVID-19): Covering past and future perspectives
Yasmin, S., & Ansari, M. Y. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107398 · Cited by 6
Association between atherogenic index of plasma and risk of type 2 diabetes mellitus and the mediating effect of BMI: a comparative analysis in Chinese and Japanese populations
Liao, Y., Han, Y. Y., Cao, C., Song, H., & Hu, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01907-1 · Cited by 6
Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence
Tselios, K., & Skendros, P. (2020) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2020.2064 · Cited by 6
Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?
Oymak, Y., Karapınar, T. H., & Devrim, İ. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001864 · Cited by 6
Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality
Rivera‐Izquierdo, M., Valero-Ubierna, M. D. C., R-delAmo, J. L., Fernández-García, M. Á., Martínez-Diz, S., Tahery-Mahmoud, A., Rodríguez-Camacho, M., Gámiz-Molina, A. B., Gyengo, N. B., Gámez-Baeza, P., et al. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.06.024 · Cited by 6
A Dedicated Veno-Venous Extracorporeal Membrane Oxygenation Unit during a Respiratory Pandemic: Lessons Learned from COVID-19 Part II: Clinical Management
Shah, A. M., Dave, S. B., Galvagno, S. M., George, K., Menne, A. R., Haase, D., McCormick, B. M., Rector, R. P., Dahi, S., Madathil, R. J., et al. (2021) · Membranes · doi:10.3390/membranes11050306 · Cited by 6
Antiviral treatment selection for SARS-CoV-2 pneumonia
Bassetti, M., Corcione, S., Dettori, S., Lombardi, A., Lupia, T., Vena, A., Rosa, F. G. D., Gori, A., & Giacobbe, D. R. (2021) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.1927719 · Cited by 6
Fast prototyping of a local fuzzy search system for decision support and retraining of hospital staff during pandemic
Bakin, E. A., Stanevich, O. V., Danilenko, D., Lioznov, D. A., & Куликов, А. Н. (2021) · Health Information Science and Systems · doi:10.1007/s13755-021-00150-y · Cited by 6
Anti-rheumatic drugs as potential anti-inflammatory, immunomodulatory agents against COVID-19: A systematic review
Sinaei, R., Pezeshki, S., Asadipour, A., Shiari, R., Sinaei, R., & Sinaei, A. (2021) · Pharmaceutical Sciences · doi:10.34172/ps.2021.40 · Cited by 6
Comunicação em saúde e desinformação sobre COVID-19 em fact-checking de fake News
Lira, A. I. D. O., Pennafort, V. P. D. S., dos Anjos, J. S. F., Barra, I. P., Costa, E. D. O., & de Mendonça, A. E. O. (2022) · Revista de Enfermagem da UFSM · doi:10.5902/2179769271263 · Cited by 6
Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care
Palazzuoli, A., Beltrami, M., & McCullough, P. A. (2023) · Biomedicines · doi:10.3390/biomedicines11030790 · Cited by 6
COVID-19 and cardiovascular complications: updates of emergency medicine
Zhao, J., Xie, Y., Meng, Z., Liu, C., Wu, Y., Zhao, F., Ma, X., Christopher, T. A., Lopez, B., & Wang, Y. (2023) · Emergency and Critical Care Medicine · doi:10.1097/ec9.0000000000000095 · Cited by 6
Reperfusion strategies on the clinical outcomes of ST-elevation myocardial infarction patients over 80 years old in China
Qu, X., Guan, S., Cai, J., Gan, Q., Han, W., Lu, L., Fang, W., Yin, P., Shi, H., Wang, A., et al. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae013 · Cited by 6
COVID‑19 in China: From epidemiology to treatment (Review)
Chen, H., Wu, S., & Zhang, X. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9353 · Cited by 6
SARS-CoV-2 / COVID-19 PANDEMIC – AN UPDATE
Shanmugam, R., Sangeetha, T., Fathah, Z., Yatoo, M. I., Tiwari, R., Pandey, M. K., Dhama, J., Chandra, R., Malik, Y. S., Dhama, K., et al. (2020) · Journal of Experimental Biology and Agricultural Sciences · doi:10.18006/2020.8(spl-1-sars-cov-2).s219.s245 · Cited by 6
Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial
Agustí, A., Guillén, E., Ayora, A., Antón, A., Aguilera, C., Vidal, X., Andrés, C., Alonso, M., Espuga, M., Esperalba, J., et al. (2020) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2020.10.023 · Cited by 6
Rapid Assessment of Proarrhythmic Potential Using Human iPSC-Derived Cardiomyocytes
Geiger, R. M., Klein, M. G., Fatima, N., Goldstein, R. E., Krantz, M. J., Haigney, M. C., & Flagg, T. P. (2020) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2020.08.034 · Cited by 6
Familiar dermatologic drugs as therapies for COVID-19
Ortega-Peña, M., & González‐Cuevas, R. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2020.09.015 · Cited by 6

Authors: Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., Sobieszczyk, M. E., & Schluger, N. W.
Affiliations: Columbia University Irving Medical Center (US)
Corresponding author: Schluger, Neil W.
ORCID: Geleris, Joshua
Sun, Yifei
Platt, Jonathan
Zucker, Jason
Baldwin, Matthew
Hripcsak, George
Manson, Daniel K.
Kubin, Christine
Barr, R. Graham
Sobieszczyk, Magdalena E.
Schluger, Neil W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-06-18
Volume: 382
Issue: 25
Pages: 2411-2418
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2012410
PMC: PMC7224609
OpenAlex: W3023346879
Cited by: 1,625
References: 17
Citations by year: 2026: 16 · 2025: 23 · 2024: 57 · 2023: 80 · 2022: 167 · 2021: 440 · 2020: 839
FWCI: 49.99
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (RO1-HL077612, RO1-HL093081, RO1-HL121270, RO1-LM006910)
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (200-2009-32593)
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: hydroxychloroquine, COVID-19 pandemic, mechanical ventilation, intubation, mortality, hospitalized patients, antimalarial drugs, treatment efficacy, propensity score weighting, SARS-CoV-2
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Aged, 80 and over, Female, Hospitalization, Humans, Hydroxychloroquine, Intubation, Male, Middle Aged, New York City, Pneumonia, Viral, Treatment Failure, Coronavirus Infections, Propensity Score, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks